{"id":2494,"date":"2022-12-20T11:44:55","date_gmt":"2022-12-20T16:44:55","guid":{"rendered":"https:\/\/labs.icahn.mssm.edu\/design\/?page_id=2494"},"modified":"2024-08-07T13:52:50","modified_gmt":"2024-08-07T17:52:50","slug":"publications","status":"publish","type":"page","link":"https:\/\/labs.icahn.mssm.edu\/zamarinlab\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Fullwidth Header &#8211; Background Title Description &#8211; no slider &#8211; Section 1 &#8221; module_class=&#8221;header-title-desciption-no-slider-section1&#8243; _builder_version=&#8221;4.9.0&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;rgba(0,174,239,0.09)&#8221; background_enable_color=&#8221;off&#8221; background_image=&#8221;https:\/\/labs.icahn.mssm.edu\/zamarinlab\/wp-content\/uploads\/sites\/510\/2022\/07\/ai-002-1.jpg&#8221; parallax=&#8221;on&#8221; custom_padding=&#8221;||||false|false&#8221; bottom_divider_style=&#8221;ramp2&#8243; bottom_divider_color=&#8221;#FFFFFF&#8221; bottom_divider_height=&#8221;11vw&#8221; bottom_divider_arrangement=&#8221;above_content&#8221; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; collapsed=&#8221;on&#8221;][et_pb_row column_structure=&#8221;1_2,1_2&#8243; _builder_version=&#8221;4.9.0&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;RGBA(0,0,0,0)&#8221; border_color_all=&#8221;RGBA(0,0,0,0)&#8221;][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.9.0&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;10%||8vw||false|false&#8221; custom_padding_tablet=&#8221;0vw||0vw||true|false&#8221; custom_padding_phone=&#8221;&#8221; custom_padding_last_edited=&#8221;on|tablet&#8221;][et_pb_text admin_label=&#8221;Text &#8211; Title&#8221; _builder_version=&#8221;4.9.0&#8243; _module_preset=&#8221;b3e3ff14-5f5c-4608-8ecf-1885ce3da7aa&#8221; header_font=&#8221;||||||||&#8221; header_text_color=&#8221;#FFFFFF&#8221; header_font_size=&#8221;48px&#8221; header_line_height=&#8221;60px&#8221; custom_margin=&#8221;||10px||false|false&#8221; header_font_size_tablet=&#8221;40px&#8221; header_font_size_phone=&#8221;24px&#8221; header_font_size_last_edited=&#8221;on|desktop&#8221;]<\/p>\n<h1><strong>Publications<\/strong><\/h1>\n<p>[\/et_pb_text][et_pb_text admin_label=&#8221;Text &#8211; Description&#8221; _builder_version=&#8221;4.9.0&#8243; _module_preset=&#8221;da86b6f0-f83c-4c7c-bdd8-3019777ddffe&#8221; text_font=&#8221;||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_font_size=&#8221;20px&#8221; text_line_height=&#8221;32px&#8221; text_font_size_tablet=&#8221;15px&#8221; text_font_size_phone=&#8221;14px&#8221; text_font_size_last_edited=&#8221;on|desktop&#8221;]<\/p>\n<p>Following is a list of our selected publications. You can click on the name of the paper to be taken directly to the PubMed link for the paper. To see the full list, please <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/myncbi\/dmitriy.zamarin.1\/bibliography\/public\/\">click here<\/a>. Additionally, to read about recent news highlighting our work, please <a href=\"https:\/\/scholars.mssm.edu\/en\/persons\/dmitriy-zamarin\/clippings\/\">click here<\/a>.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_2&#8243; _builder_version=&#8221;4.9.0&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;RGBA(0,0,0,0)&#8221;][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Section 28 &#8211; Blog Style Publications&#8221; module_class=&#8221;section28_blog_style_publications&#8221; _builder_version=&#8221;4.9.0&#8243; background_color=&#8221;#FFFFFF&#8221; background_image=&#8221;https:\/\/labs.icahn.mssm.edu\/zamarinlab\/wp-content\/uploads\/sites\/510\/2022\/10\/Background-1.png&#8221; parallax=&#8221;on&#8221; parallax_method=&#8221;off&#8221; custom_padding=&#8221;50px||||false|false&#8221; global_module=&#8221;2511&#8243; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; collapsed=&#8221;on&#8221;][et_pb_row _builder_version=&#8221;4.9.0&#8243; _module_preset=&#8221;default&#8221; custom_padding=&#8221;||4px|||&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.9.0&#8243; _module_preset=&#8221;default&#8221;][et_pb_text _builder_version=&#8221;4.9.0&#8243; _module_preset=&#8221;default&#8221;]<\/p>\n<ul>\n<li style=\"text-align: justify\">\n<div class=\"citation-text\">Friedman CF, Manning-Geist BL, Zhou Q, Soumerai T, Holland A, Da Cruz Paula A, Green H, Ozsoy MA, Iasonos A, Hollmann T, Leitao MM Jr, Mueller JJ, Makker V, Tew WP, O&#8217;Cearbhaill RE, Liu YL, Rubinstein MM, Troso-Sandoval T, Lichtman SM, Schram A, Kyi C, Grisham RN, Causa Andrieu P, Wherry EJ, Aghajanian C, Weigelt B, Hensley ML, <strong>Zamarin D<\/strong>. Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses. Nat Med. 2024 May;30(5):1330-1338. doi: 10.1038\/s41591-024-02942-7. Epub 2024 Apr 23. PMID: 38653864; PMCID: PMC11108776.<\/div>\n<div class=\"citation-actions\"><\/div>\n<\/li>\n<li style=\"text-align: justify\"><span data-ogsc=\"black\">Brodeur MN, Dopeso H, Zhu Y, Longhini ALF, Gazzo A, Sun S, Koche R, Qu R, Hamard PJ, Bykov Y, Green H, Chiappinelli KB, Ozsoy MA, Basili T, Gardner R, Walderich S, DeStanchina E, Greenbaum B, G\u00f6nen M, Weigelt B,\u00a0<strong>Zamarin D. <\/strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37609261\/\">Interferon response and epigenetic modulation by SMARCA4 mutations drive ovarian tumor immunogenicity<\/a>. <em>bioRxiv<\/em>. 2023 Aug 11:2023.08.08.552544.<\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><span data-ogsc=\"black\"><span data-ogsc=\"black\">Duska LR,\u00a0<strong>Zamarin D<\/strong>, Hamilton E, Oza A, Fleming G, Spira A, Yeku OO, Richardson DL, Walling J, Inokuchi K, Matusow B, Bollag G, Swisher EM. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37797273\/\">Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib\/IIa Study of PLX2853\/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer<\/a>. <em>JCO Precis Oncol<\/em>. 2023 Sep;7:e2300235<\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><span data-ogsc=\"black\"><span data-ogsc=\"black\">Lam C, Sarasohn D, Weigelt B, <strong>Zamarin D. <\/strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37636495\/\">Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer.<\/a> <em>Gynecol Oncol Rep<\/em>. 2023 Aug 11;49:101258.<\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Khushalani NI, Harrington KJ, Melcher A, Bommareddy PK, <strong>Zamarin D<\/strong>. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37841530\/\">Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment<\/a>. <em>Mol Ther Oncolytics<\/em>. 2023 Sep 19;31:100729\\<\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Henson CE, Morton DJ, Mayadev JS, Wong SJ, <strong style=\"font-size: 16px;text-align: left\">Zamarin D<\/strong><span style=\"font-size: 16px;text-align: left\">. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36576320\/\">Cancer trials as opportunities to serve and learn from individuals with human immunodeficiency virus. <\/a><\/span><em style=\"font-size: 16px;text-align: left\">Cancer<\/em><span style=\"font-size: 16px;text-align: left\"><span style=\"font-size: 16px;text-align: left\">. 2023 Mar 1;129(5):664-667.<\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Dessources K, Ferrando L, Zhou QC, Iasonos A, Abu-Rustum NR, Reis-Filho JS, Riaz N,\u00a0<strong style=\"font-size: 16px;text-align: left\">Zamarin D*<\/strong><span style=\"font-size: 16px;text-align: left\">, <\/span><strong style=\"font-size: 16px;text-align: left\">Weigelt B*.<\/strong><span style=\"font-size: 16px;text-align: left\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36804617\/\"> Impact of immune infiltration signatures on prognosis in endometrial carcinoma is dependent on the underlying molecular subtype<\/a>. <\/span><em style=\"font-size: 16px;text-align: left\">Gynecol Oncol<\/em><span style=\"font-size: 16px;text-align: left\">. 2023 Apr;171:15-22. <\/span><em style=\"font-size: 16px;text-align: left\">*equal contribution<\/em><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Liu YL, <strong style=\"font-size: 16px;text-align: left\">Zamarin D<\/strong><span style=\"font-size: 16px;text-align: left\">. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36700799\/\">Shedding light on PARP inhibitor response through functional imaging<\/a>. <\/span><em style=\"font-size: 16px;text-align: left\">Clin Cancer Res<\/em><span style=\"font-size: 16px;text-align: left\"><span style=\"font-size: 16px;text-align: left\">. 2023 Apr 14;29(8):1384-1386.<\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><span data-ogsc=\"black\"> <\/span><span data-ogsc=\"black\"><span data-ogsc=\"black\">Rubinstein MM, Doria ER, Konner J, Lichtman S, Zhou Q, Iasonos A, Sarasohn D, Troso-Sandoval T, Friedman C, O&#8217;Cearbhaill R, Cadoo K, Kyi C, Cohen S, Soldan K, Billinson E, Caird I, Jang D, Eid K, Shah P, Guillen J, Aghajanian C,\u00a0<strong>Zamarin D<\/strong>, Makker V. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36512912\/\">Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study<\/a>. <em>Gynecol Oncol<\/em>. 2023 Feb;169:64-69.<\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><span data-ogsc=\"black\"> <\/span><span data-ogsc=\"black\"><span data-ogsc=\"black\"><span data-ogsc=\"black\"><span data-ogsc=\"black\">V\u00e1zquez-Garc\u00eda I, Uhlitz F, Ceglia N, Lim JLP, Wu M, Mohibullah N, Niyazov J, Ruiz AEB, Boehm KM, Bojilova V, Fong CJ, Funnell T, Grewal D, Havasov E, Leung S, Pasha A, Patel DM, Pourmaleki M, Rusk N, Shi H, Vanguri R, Williams MJ, Zhang AW, Broach V, Chi DS, Da Cruz Paula A, Gardner GJ, Kim SH, Lennon M, Long Roche K, Sonoda Y, Zivanovic O, Kundra R, Viale A, Derakhshan FN, Geneslaw L, Issa Bhaloo S, Maroldi A, Nunez R, Pareja F, Stylianou A, Vahdatinia M, Bykov Y, Grisham RN, Liu YL, Lakhman Y, Nikolovski I, Kelly D, Gao J, Schietinger A, Hollmann TJ, Bakhoum SF, Soslow RA, Ellenson LH, Abu-Rustum NR, Aghajanian C, Friedman CF, McPherson A, Weigelt B, <strong>Zamarin D*<\/strong>, <strong>Shah SP*<\/strong>.\u00a0<\/span><\/span><\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36517593\/\">Ovarian cancer mutational processes drive site-specific immune evasion<\/a>.\u00a0<em>Nature. 2022 Dec;612(7941):778-786.<\/em> <em>*equal contribution<\/em><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><span data-ogsc=\"black\"> <\/span><span data-ogsc=\"black\"><span data-ogsc=\"black\">Funnell T, O&#8217;Flanagan CH, Williams MJ, McPherson A, McKinney S, Kabeer F, Lee H, Salehi S, V\u00e1zquez-Garc\u00eda I, Shi H, Leventhal E, Masud T, Eirew P, Yap D, Zhang AW, Lim JLP, Wang B, Brimhall J, Biele J, Ting J, Au V, Van Vliet M, Liu YF, Beatty S, Lai D, Pham J, Grewal D, Abrams D, Havasov E, Leung S, Bojilova V, Moore RA, Rusk N, Uhlitz F, Ceglia N, Weiner AC, Zaikova E, Douglas JM, <strong>Zamarin D<\/strong>, Weigelt B, Kim SH, Da Cruz Paula A, Reis-Filho JS, Martin SD, Li Y, Xu H, de Algara TR, Lee SR, Llanos VC, Huntsman DG, McAlpine JN; IMAXT Consortium, Shah SP, Aparicio S. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36289342\/\">Single-cell genomic variation induced by mutational processes in cancer<\/a>. <em>Nature<\/em>. 2022 Oct 26. doi: 10.1038\/s41586-022-05249-0. Online ahead of print.<\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Hoyos D, Zappasodi R, Schulze I, Sethna Z, de Andrade KC, Bajorin DF, Bandlamudi C, Callahan MK, Funt SA, Hadrup SR, Holm JS, Rosenberg JE, Shah SP, V\u00e1zquez-Garc\u00eda I, Weigelt B, Wu M,\u00a0<strong style=\"font-size: 16px\">Zamarin D<\/strong><span style=\"font-size: 16px\">, Campitelli LF, Osborne EJ, Klinger M, Robins HS, Khincha PP, Savage SA, Balachandran VP, Wolchok JD, Hellmann MD, Merghoub T, Levine AJ, \u0141uksza M, Greenbaum BD. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35545680\/\">Fundamental immune-oncogenicity trade-offs define driver mutation fitness<\/a>. <\/span><em style=\"font-size: 16px\">Nature<\/em><span style=\"font-size: 16px\"><span style=\"font-size: 16px\">. 2022 Jun;606(7912):172-179.<\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Boehm KM, Aherne EA, Ellenson L, Nikolovski I, Alghamdi M, V\u00e1zquez-Garc\u00eda I, <strong style=\"font-size: 16px\">Zamarin D<\/strong><span style=\"font-size: 16px\">, Roche KL, Liu Y, Patel D, Aukerman A, Pasha A, Rose D, Selenica P, Causa Andrieu PI, Fong C, Capanu M, Reis-Filho JS, Vanguri R, Veeraraghavan H, Gangai N, Sosa R, Leung S, McPherson A, Gao J; MSK MIND Consortium, Lakhman Y, Shah SP. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35764743\/\">Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer<\/a>. <\/span><em style=\"font-size: 16px\">Nat Cancer<\/em><span style=\"font-size: 16px\"><span style=\"font-size: 16px\">. 2022 Jun;3(6):723-733<\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><span data-ogsc=\"black\"><span data-ogsc=\"black\">Ma X, Riaz N, Samstein RM, Lee M, Makarov V, Valero C, Chowell D, Kuo F, Hoen D, Fitzgerald CWR, Jiang H, Alektiar J, Alban TJ, Juric I, Parthasarathy PB, Zhao Y, Sabio EY, Verma R, Srivastava RM, Vuong L, Yang W, Zhang X, Wang J, Chu LK, Wang SL, Kelly DW, Pei X, Chen J, Yaeger R,\u00a0<strong>Zamarin D<\/strong>, Zehir A, G\u00f6nen M, Morris LGT, Chan TA. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35817971\/\">Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity<\/a>. <em>Nat Genet.<\/em> 2022 Jul;54(7):996-1012<\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Sia TY, Manning-Geist B, Gordhandas S, Murali R, Marra A, Liu YL, Friedman CF, Hollmann TJ, Zivanovic O, Chi DS, Weigelt B, Konner JA,\u00a0<strong>Zamarin D. <\/strong><span data-ogsc=\"black\" style=\"font-size: 16px\"><span data-ogsc=\"black\" style=\"font-size: 16px\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35545291\/\">Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series<\/a>. <em>Int J Gynecol Cancer<\/em>. 2022; 8:1017.<\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Osorio JC, <strong style=\"font-size: 16px;text-align: left\">Zamarin D<\/strong><span style=\"font-size: 16px;text-align: left\"><span style=\"font-size: 16px;text-align: left\">. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35247898\/\">Beyond T cells: IgA incites immune recognition in endometrial cancer<\/a>. Cancer Res. 2022 Mar 1;82(5):766-768<\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Chae CS, Sandoval TA, Hwang SM, Park ES, Giovanelli P, Awasthi D, Salvagno C, Emmanuelli A, Tan C, Chaudhary V, Casado J, Kossenkov AV, Song M, Barrat FJ, Holcomb K, Romero-Sandoval EA,\u00a0<strong style=\"font-size: 16px\">Zamarin D<\/strong><span style=\"font-size: 16px\">, Pepin D, D&#8217;Andrea AD, Farkkila A, Cubillos-Ruiz JR. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35552618\/\">Tumor-derived Lysophosphatidic Acid Blunts Protective Type-I Interferon Responses in Ovarian Cancer<\/a>. <\/span><em style=\"font-size: 16px\">Cancer Discov<\/em><span style=\"font-size: 16px\"><span style=\"font-size: 16px\">. 2022 Aug 5;12(8):1904-1921.<\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Ethier JL, Fuh KC, Arend R, Konecny GE, Konstantinopoulos PA, Odunsi K, Swisher EM, Kohn EC, <strong style=\"font-size: 16px;text-align: left\">Zamarin D<\/strong><span style=\"font-size: 16px;text-align: left\"><span style=\"font-size: 16px;text-align: left\">. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36240472\/\">State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report<\/a>. JCO Precis Oncol. 2022 Oct;6:e2200355. doi: 10.1200\/PO.22.00355.<\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Uhlitz F, <strong>Zamarin <\/strong>D. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34739843\/\">Rejuvenating dysfunctional T cells in ovarian cancer: CD28 is the license to kill<\/a>. <em>Cancer Cell<\/em>. 2021 Dec 13;39(12):1567-1569.<\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Shamseddine AA, Burman B, Lee NY, <strong>Zamarin D<\/strong>, Riaz N. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33990345\/\">Tumor Immunity and Immunotherapy for HPV-Related Cancers<\/a>. <em>Cancer Discov<\/em>. 2021; 11(8):1896-1912<\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><span data-ogsc=\"black\"> <\/span><span data-ogsc=\"black\"><span data-ogsc=\"black\"><span data-ogsc=\"black\">Chow A, Schad S, Green MD, Hellmann MD, Allaj V, Ceglia N, Zago G, Shah NS, Sharma SK, Mattar M, Chan J, Rizvi H, Zhong H, Liu C, Bykov Y, <strong>Zamarin D<\/strong>, Shi H, Budhu S, Wohlhieter C, Uddin F, Gupta A, Khodos I, Waninger JJ, Qin A, Markowitz GJ, Mittal V, Balachandran V, Durham JN, Le DT, Zou W, Shah SP, McPherson A, Panageas K, Lewis JS, Perry JSA, de Stanchina E, Sen T, Poirier JT, Wolchok JD, Rudin CM, Merghoub T. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34115989\/\">Tim-4<sup>+<\/sup> cavity-resident macrophages impair anti-tumor CD8<sup>+<\/sup> T\u00a0cell immunity. <em>Cancer Cell<\/em><\/a>. 2021 Jul 12;39(7):973-988<\/span><\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><span data-ogsc=\"black\"> <\/span><span data-ogsc=\"black\"><span data-ogsc=\"black\"><span data-ogsc=\"black\">Friedman CF, Snyder A, de Meritens AB, Cantrell L, Corr B, Fu S, Konner J, Konstatinopoulos P, Iasonos A, Aghajanian C, <strong>Zamarin D.<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33004542\/\">A Phase 2 Study of Atezolizumab in Combination with Bevacizumab in Patients with Recurrent, Persistent or Metastatic Cervical Cancer<\/a>. <em>J. Immunother. Cancer (<\/em>2020)<em>. e001126.<\/em><\/span><\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><span data-ogsc=\"black\"> <\/span><strong><span data-ogsc=\"black\">Zamarin D<\/span><\/strong><span data-ogsc=\"black\">, Hamid O, Nayak-Kapoor A, Sahebjam S, Sznol M, Collaku A, Fox FE, Marshall M, Hong D. <\/span><span data-ogsc=\"black\"><span data-ogsc=\"black\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32586937\/\">Regulatory T cell depletion with Mogamulizumab in Combination with the Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: a Phase I Study<\/a>. <em>Clin. Canc. Res. <\/em>26(17):4531-4541 (2020).<\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><span data-ogsc=\"black\"> <\/span><strong><span data-ogsc=\"black\">Zamarin D, <\/span><\/strong><span data-ogsc=\"black\"><span data-ogsc=\"black\"><span data-ogsc=\"black\">O\u2019Cearbhaill RE, Holland A, Walderich S, Cadoo KA, Gallagher J, Kravetz S, Mcdonnell A, Troso-Sandoval T, Sabbatini P, Lichtman S, Tew W, Makker V, Grisham RN, Hyman DM, Erskine C, Block MS, Knutson KL, Aghajanian C, Konner JA. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32503949\/\">Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial<\/a>. <em>J. Immunother. Cancer <\/em>2020. Jun;8(1):e000829<em> Epub ahead of print.<\/em><\/span><\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><em><span data-ogsc=\"black\"> <\/span><\/em><span data-ogsc=\"black\">Boland JL, Zhou Q, Iasonos AE, O\u2019Cearbhaill R, Konner J, Callahan M, Friedman C, Aghajanian C, Sabbatini P, <strong>Zamarin D<sup>*<\/sup><\/strong>, Cadoo KA<sup>*<\/sup> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32507515\/\">Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy<\/a>. <\/span><em><span data-ogsc=\"black\">Gynecol Oncol. <\/span><\/em><span data-ogsc=\"black\">152(2):251-258 (<\/span><span data-ogsc=\"black\">2020).<\/span><em><span data-ogsc=\"black\"><\/span><\/em><span data-ogsc=\"black\"><span data-ogsc=\"black\">*equal contribution<\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><strong><span data-ogsc=\"black\"> <\/span><\/strong><span data-ogsc=\"black\"><span data-ogsc=\"black\"><span data-ogsc=\"black\">Liu YL, Selenica P, Zhou Q, Iasonos A, Callahan M., Feit ZH, Boland J, Vazquez-Garcia I, Mandelker D, Zehir A, Burger RA, Powell DJ, Friedman C, Cadoo K, Grisham R, Konner JA, O\u2019Cearbhaill RE, Aghajanian C, Reis-Filho JS, Weigelt B, <strong>Zamarin D.<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32923884\/\"><em>BRCA<\/em> Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer<\/a>. <em>JCO Prec. Oncol <\/em>2020 Jun 16;4:PO.20.00069. <em>Epub ahead of print.<\/em><\/span><\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><strong>Zamarin D,<\/strong> Burger RA, Sill MW, Powell DJ, Zivanovic O, Gunderson C, Ko E, Mathews C, Sharma S, Hagemann AR, Khleif S, Aghajanian C. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32275468\/\">A Randomized Phase II Trial Of Nivolumab Vs. Nivolumab And Ipilimumab For Recurrent Or Persistent Ovarian Cancer: An NRG Oncology Study<\/a>. <em>J. Clin Oncol. 38:1814 (2020).<\/em><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Bykov Y, Kim SH, <strong>Zamarin D.<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32000902\/\">Preparation of single cells from tumors for single-cell RNA sequencing<\/a>. <em>Methods in Enzymology. <\/em>2020; 632: 295-308<\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Liu YL, Zhou Q, Iasonos A, Emengo VN, Friedman C, Konner JA, O&#8217;Cearbhaill RE, Aghajanian C, <strong>Zamarin D.<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31421916\/\">Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer<\/a>. <span data-ogsc=\"\"><em>Gynecol Oncol<\/em><\/span><em>.<\/em> 2019 Oct;155(1):51-57<\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Scott AC, D\u00fcndar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, Trivedi P, Menocal L, Appleby H, Camara SJ, <strong>Zamarin D<\/strong>, Walther T, Snyder AC, Femia MR, Comen EA, Wen HY, Hellmann MD, Anandasabapathy N, Liu Y, Altorki NK, Lauer P, Levy O, Glickman M, Kaye J, Betel D, Philip M, Schietinger A. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31207604\/\">TOX is a critical regulator of tumour-specific T cell differentiation<\/a>. <em>Nature.<\/em> 2019 Jul;571(7764):270-274<\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Vijayakumar G,<strong> Zamarin D. <\/strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31486036\/\">Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation<\/a>. <em>Methods in Molecular Biology. <\/em>2020; 2058:133-154.<\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Burman B, Pesci G,<strong> Zamarin D.<\/strong> <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33260685\/\">Newcastle Disease Virus at the Forefront of Cancer Immunotherapy<\/a>. \u00a0<em>Cancers (Basel).<\/em> 2020 Nov 28;12(12):E3552.<\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><strong>Zamarin D. <\/strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31586519\/\">Immunomodulatory Drugs Encoded by Oncolytic Viruses: Is the Whole Greater Than the Sum?<\/a> <em>Mol. Ther <\/em><span data-ogsb=\"white\">6;27(11):1874-1877<\/span> (2019).<\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Jelinic P, Ricca J, Van Oudenhove E, Olvera N, Merghoub T, Levine DA, <strong>Zamarin D<\/strong>. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29365144\/\">Immune-active microenvironment in SCCOHT: rationale for therapy with immune checkpoint blockade<\/a>. J. Natl. Cancer Inst. 2018; Jul 1;110(7):787-790.<\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><span><strong>Zamarin D.,<\/strong><\/span><span><span><span> Ricca J.M., Sadekova S., Oseledchyk A., Yu Y., Blumenschein W.M., Wong J., Gigoux M., Merghoub T., Wolchok J.D. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29504948\/\">PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy<\/a>. J. Clin. Invest. 2018 Apr 2;128(4):1413-1428<\/span><\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><span><span><span>Ricca J., Oseledchyk A., Walther T., Liu C., Mangarin L., Merghoub T., Wolchok J.D., <strong>Zamarin D.<\/strong>\u00a0 <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29478729\/\">Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy<\/a>. Mol. Ther. 2018 Apr 4;26(4):1008-1019<\/span><\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><span><span><span>Oseledchyk A., Gennarelli R.L., Leitao M.M., Aghajanian C.A., Iasonos A., Zivanovic O., <strong>Zamarin D.\u00a0<\/strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29667339\/\">Adjuvant Chemotherapy in Patients with Operable Granulosa Cell Tumors of the Ovary: A Surveillance, Epidemiology, and End Results Cohort Study<\/a>. Cancer Medicine. 2018 Jun;7(6):2280-2287<\/span><\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><span><span>Oseledchyk A., Ricca J.M., Gigoux M., Ko B., Redelman-Sidi G., Walther T., Liu C., Iyer G., Merghoub T., Wolchok J.D., <strong>Zamarin D. <\/strong><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/29983890\/\">Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus<\/a>. Oncotarget. 2018 Jun 19;9(47):28702-28716<\/span><\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Bykov Y, <strong>Zamarin D<\/strong>. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/30530816\/\">Virus, vessel, victory: a novel approach to tumor killing<\/a>. <span data-ogsc=\"\"><em>Clin Cancer Res<\/em><\/span>. 2018<\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Ricca J., Oseledchyk A., <strong>Zamarin D. <\/strong><a href=\"https:\/\/www.targetedonc.com\/view\/locoregional-therapeutics-using-ones-own-tumor-as-a-vaccine\">Locoregional therapeutics: using one\u2019s own tumor as a vaccine<\/a>. <em>Targeted Oncology.<\/em> <span data-ogsb=\"white\">19:172-181<\/span> (2017)<em>.<\/em><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Jim\u00e9nez-S\u00e1nchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, Gill MB, Park KJ, Zivanovic O, Konner J, Ricca J, <strong>Zamarin D<\/strong>, Walther T, Aghajanian C, Wolchok JD, Sala E, Merghoub T, Snyder A, Miller ML. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28841418\/\">Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient<\/a>. <em>Cell <\/em>2017<em>; <\/em>170: 927-938.<\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><strong>Zamarin D., <\/strong>Holmgaard R.B., Ricca J., Plitt T., Palese P., Sharma P., Merghoub T., Wolchok J.D., Allison J.P. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28194010\/\">Intratumoral modulation of the inducible costimulator (ICOS) by recombinant oncolytic virus promotes systemic anti-tumor immunity<\/a>. <em>Nat Commun <\/em>2017<em>; <\/em>8:14340.<\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Holmgaard R.B., <strong>Zamarin D.<\/strong>, Lesokhin A., Merghoub T., Wolchok J.D. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27211548\/\">CSF-1 receptor blockade overcomes resistance to immunomodulatory antibody and IDO-based immunotherapy in MDSC-driven tumors<\/a>.<em> Ebiomedicine <\/em>2016; 6:50-8<em>.<\/em><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><strong>Zamarin D.<\/strong> and Jazaeri A.A. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/27016233\/\">Leveraging Immunotherapy for the treatment of Gynecologic Cancers in the Era of Precision Medicine<\/a>. <em>Gynecologic Oncology. <\/em>141:86-94 (2016)<em>.<\/em><\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\">Holmgaard R.B., <strong>Zamarin D.<\/strong>, Li Y., Gasmi B., Munn D.H., Allison J.P., Merghoub T., Wolchok J.D. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26411680\/\">Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner<\/a>. <em>Cell Reports<\/em>. 2015;13:412-24.<\/li>\n<\/ul>\n<ul>\n<li style=\"text-align: justify\"><strong>Zamarin D.,<\/strong> Holmgaard R.B., Subudhi S.K., Park J., Mansour M., Palese P., Merghoub T., Wolchok J.D., and Allison J.P. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/24598590\/\">Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy<\/a>. <em>Sci. Transl. Med.<\/em>2014; 6:226ra32<em>.<\/em><em> <\/em><\/li>\n<\/ul>\n<p><em><\/em><\/p>\n<ul>\n<li style=\"text-align: justify\">Holmgaard R.B., <strong>Zamarin D<\/strong>., Munn D.H., Wolchok J.D., and Allison J.P. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23752227\/\">Indoleamine 2,3-dioxygenase is a critical mechanism of resistance for anti-tumor T-cell immunotherapies targeting immune checkpoints<\/a>. <em>J. Exp. Med.<\/em> 2013; 210:1389-402.<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; disabled_on=&#8221;off|off|off&#8221; admin_label=&#8221;Footer Fullwidth &#8211; Section 13&#8243; module_class=&#8221;footer-section&#8221; _builder_version=&#8221;4.9.0&#8243; background_color=&#8221;#c7eafb&#8221; background_image=&#8221;https:\/\/labs.icahn.mssm.edu\/zamarinlab\/wp-content\/uploads\/sites\/510\/2022\/10\/Rectangle-3.png&#8221; max_width=&#8221;100%&#8221; max_width_tablet=&#8221;&#8221; max_width_phone=&#8221;&#8221; max_width_last_edited=&#8221;on|phone&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;86px|||176px|false|false&#8221; custom_padding=&#8221;3px|0px|0px|0px|false|false&#8221; animation_style=&#8221;slide&#8221; animation_direction=&#8221;bottom&#8221; animation_intensity_slide=&#8221;14%&#8221; animation_starting_opacity=&#8221;100%&#8221; global_module=&#8221;3741&#8243; saved_tabs=&#8221;all&#8221; locked=&#8221;off&#8221; collapsed=&#8221;on&#8221;][et_pb_row _builder_version=&#8221;4.9.0&#8243; background_color=&#8221;RGBA(0,0,0,0)&#8221; background_color_gradient_direction=&#8221;38deg&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;|auto||147px||&#8221; custom_padding=&#8221;1px|||||&#8221; locked=&#8221;off&#8221; collapsed=&#8221;off&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_social_media_follow _builder_version=&#8221;4.9.0&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;RGBA(0,0,0,0)&#8221; text_orientation=&#8221;center&#8221;][et_pb_social_media_follow_network social_network=&#8221;twitter&#8221; url=&#8221;https:\/\/twitter.com\/DmitriyZamarin&#8221; use_icon_font_size=&#8221;on&#8221; icon_font_size=&#8221;24px&#8221; _builder_version=&#8221;4.9.0&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;RGBA(0,0,0,0)&#8221; background_enable_color=&#8221;on&#8221; follow_button=&#8221;off&#8221; url_new_window=&#8221;on&#8221;]twitter[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][et_pb_text _builder_version=&#8221;4.9.0&#8243; _module_preset=&#8221;default&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_font_size=&#8221;24px&#8221;]<\/p>\n<p style=\"text-align: center\"><strong>Contact Us<\/strong><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=&#8221;1_3,1_3,1_3&#8243; _builder_version=&#8221;4.9.0&#8243; background_color=&#8221;RGBA(0,0,0,0)&#8221; background_color_gradient_direction=&#8221;38deg&#8221; module_alignment=&#8221;center&#8221; custom_margin=&#8221;|auto|-2px|auto||&#8221; custom_padding=&#8221;0px||0px|||&#8221; locked=&#8221;off&#8221; collapsed=&#8221;off&#8221;][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.9.0&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.9.0&#8243; _module_preset=&#8221;default&#8221; text_font=&#8221;||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;22px&#8221;]<\/p>\n<p>&nbsp;<\/p>\n<p><a href=\"https:\/\/scholars.mssm.edu\/en\/persons\/dmitriy-zamarin\/clippings\/\" style=\"font-size: 16px;color: #ffffff\">Recent News<\/a><br \/> <span style=\"font-size: 16px\"><\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.9.0&#8243; text_font=&#8221;||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;1.25em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;|700||on|||||&#8221; header_4_font_size=&#8221;16px&#8221; header_4_letter_spacing=&#8221;1px&#8221; header_4_line_height=&#8221;1.5em&#8221; background_layout=&#8221;dark&#8221; locked=&#8221;off&#8221;]<\/p>\n<p><strong>E-mail<br \/> <\/strong>zamarinlab@mssm.edu<\/p>\n<p><strong>Phone<br \/> <\/strong>Tel: 212-824-9214<\/p>\n<p>[\/et_pb_text][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;4.9.0&#8243; text_font=&#8221;||||||||&#8221; text_text_color=&#8221;#FFFFFF&#8221; text_line_height=&#8221;1.25em&#8221; header_font=&#8221;||||||||&#8221; header_4_font=&#8221;|700||on|||||&#8221; header_4_font_size=&#8221;16px&#8221; header_4_letter_spacing=&#8221;1px&#8221; header_4_line_height=&#8221;1.5em&#8221; background_layout=&#8221;dark&#8221; custom_padding=&#8221;||0px|||&#8221; locked=&#8221;off&#8221;]<\/p>\n<p><strong>Lab Address <\/strong><br \/>Hess CSM Building, Floor 5 Room S-302<br \/>1470 Madison Avenue<br \/>New York, NY 10029<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>PublicationsFollowing is a list of our selected publications. You can click on the name of the paper to be taken directly to the PubMed link for the paper. To see the full list, please click here. Additionally, to read about recent news highlighting our work, please click here. Friedman CF, Manning-Geist BL, Zhou Q, Soumerai [&hellip;]<\/p>\n","protected":false},"author":545,"featured_media":0,"parent":0,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"class_list":["post-2494","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/labs.icahn.mssm.edu\/zamarinlab\/wp-json\/wp\/v2\/pages\/2494","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/labs.icahn.mssm.edu\/zamarinlab\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/labs.icahn.mssm.edu\/zamarinlab\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/labs.icahn.mssm.edu\/zamarinlab\/wp-json\/wp\/v2\/users\/545"}],"replies":[{"embeddable":true,"href":"https:\/\/labs.icahn.mssm.edu\/zamarinlab\/wp-json\/wp\/v2\/comments?post=2494"}],"version-history":[{"count":20,"href":"https:\/\/labs.icahn.mssm.edu\/zamarinlab\/wp-json\/wp\/v2\/pages\/2494\/revisions"}],"predecessor-version":[{"id":5129,"href":"https:\/\/labs.icahn.mssm.edu\/zamarinlab\/wp-json\/wp\/v2\/pages\/2494\/revisions\/5129"}],"wp:attachment":[{"href":"https:\/\/labs.icahn.mssm.edu\/zamarinlab\/wp-json\/wp\/v2\/media?parent=2494"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}